Direkt zum Inhalt
Merck

Comparison of therapeutic lipid target achievements among high-risk patients in Oman.

Angiology (2013-04-09)
Khalid Al-Waili, Ibrahim Al-Zakwani, Tamima Al-Dughaishi, Yajnavalka Baneerje, Hilal Al-Sabti, Khamis Al-Hashmi, Hatem Farhan, Khadija Al Habsi, Ali T Al-Hinai, Khalid Al-Rasadi
ZUSAMMENFASSUNG

We compared therapeutic lipid target achievements among patients with diabetes or coronary heart disease (CHD) in Oman. A retrospective chart review of 94 patients was conducted at an outpatient clinic in Sultan Qaboos University Hospital, Muscat, Oman. The variables included low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apo B). The overall mean age of the cohort was 59 ± 12 years, 54% were male, 66% were diabetic, 48% hypertensive, 45% had CHD, 94% were on simvastatin, 4% were on fenofibrate, and 2% were on both simvastatin and fenofibrate. Lipid goal attainments of calculated LDL-C (<2.6 mmol/L), apo B (<0.9 g/L), and non-HDL-C (<3.36 mmol/L) were reached in 52%, 39%, and 53% of the patients, respectively. A significant proportion of high-risk patients treated with lipid-lowering agents reach LDL-C but not the apo B treatment targets, suggesting that the use of apo B target values should also be considered.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Simvastatin, ≥97% (HPLC), solid
Sigma-Aldrich
Fenofibrat, ≥99%, powder
Supelco
Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Fenofibrat, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Simvastatin, United States Pharmacopeia (USP) Reference Standard
USP
Fenofibrat, United States Pharmacopeia (USP) Reference Standard
Simvastatin, European Pharmacopoeia (EP) Reference Standard
Supelco
Simvastatin, analytical standard
Fenofibrat, European Pharmacopoeia (EP) Reference Standard